论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Xie J, Li N, Jiang X, Chai L, Chen JJ, Deng W
Received 13 December 2018
Accepted for publication 8 March 2019
Published 17 April 2019 Volume 2019:12 Pages 519—526
DOI https://doi.org/10.2147/DMSO.S198154
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Konstantinos Tziomalos
Background: Consistent
evidence is still lacking on which one, glimepiride plus metformin or
repaglinide plus metformin, is better in treating type 2 diabetes mellitus
(T2DM). Therefore, this study was conducted to compare the short-term efficacy
and safety of these two methods in treating T2DM.
Methods: The
literature research dating up to August 2018 was conducted in the electronic
databases. The randomized controlled trials (RCTs) comparing the short-term
(treatment period ≤12 weeks) efficacy and safety of these two methods in
treating patients with T2DM were included. No language limitation was used in
this study. The decreased hemoglobin A1c (HbA1c), fasting plasma glucose (FPG),
and 2h plasma glucose (2hPG) levels were used as the primary outcome to assess
the efficacy, and the adverse events and hypoglycemia were used as the
secondary outcome to assess the safety.
Results: In total,
11 RCTs composed of 844 T2DM patients were included. The results showed that
there were no significant differences in decreasing HbA1c and FPG levels
between the two methods, but the estimated standardized mean differences
favored the repaglinide plus metformin. Meanwhile, the repaglinide plus
metformin was significantly more effective in decreasing 2hPG levels than
glimepiride plus metformin. In addition, fewer patients reported adverse events
and experienced hypoglycemia in the repaglinide plus metformin group.
Conclusion: These
results indicated that the repaglinide plus metformin might have some
advantages over glimepiride plus metformin in the short-term treatment of
patients with T2DM, and should be further explored.
Keywords: repaglinide,
glimepiride, metformin, diabetes